Filing Details
- Accession Number:
- 0001209191-21-057982
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-28 18:59:39
- Reporting Period:
- 2021-09-24
- Accepted Time:
- 2021-09-28 18:59:39
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1382101 | Sutro Biopharma Inc. | STRO | Biological Products, (No Disgnostic Substances) (2836) | 452441988 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1877585 | Nicki Vasquez | C/O Sutro Biopharma, Inc. 310 Utah Avenue, Suite 150 South San Francisco CA 94080 | Chief Port. Strat & Alnce Ofcr | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-09-24 | 5,969 | $0.00 | 13,239 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-09-24 | 2,063 | $19.23 | 11,176 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2021-09-28 | 3,906 | $18.62 | 7,270 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Unit (RSU) | Disposition | 2021-09-24 | 5,969 | $0.00 | 5,969 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2021-09-26 | No | 4 | M | Direct |
Footnotes
- Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.47 to $19.08 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
- The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date.
Billionaire Hedge Funds
